Medicaid expansion in Southern states improves breast cancer outcomes

A woman in rural Texas with a persistent lump in her breast has a choice that a woman across the border in Louisiana does not: she can either pay out of pocket for a mammogram, or she can drive hours to find one she can afford. This gap in access—the invisible line where Medicaid coverage ends and begins—has become a measurable difference in who gets diagnosed with advanced cancer and who catches it early.

Researchers at the Orlando Health Cancer Institute and Louisiana State University Health Sciences Center set out to quantify what one senior author had observed firsthand during his years practicing medicine in Louisiana: patients traveling across state lines in search of cancer care they could not afford at home. The question was straightforward but politically fraught: does Medicaid expansion actually change outcomes for breast cancer patients? The answer, published in the Journal of the American College of Surgeons, is yes—but with complications.

The Affordable Care Act of 2010 initially expanded Medicaid to cover all adults earning up to 138 percent of the federal poverty level, roughly $17,774 annually for an individual in 2021. But a 2012 Supreme Court decision made expansion optional for states. Today, 40 states have adopted it. The South, however, remains largely resistant. To understand the regional impact, researchers compared breast cancer patients in three Southern states that expanded Medicaid—Louisiana, Kentucky, and Arkansas—against five that did not: Tennessee, Alabama, Mississippi, Texas, and Oklahoma.

The data came from nearly 22,000 patients diagnosed with invasive breast cancer between 2011 and 2018, all tracked through the North American Association of Central Cancer Registries. The findings were stark. In non-expansion states, 41 percent of breast cancer patients were uninsured. In expansion states, that figure dropped to 19 percent. That difference—more than a 50 percent reduction in uninsured rates—translated into earlier detection. Patients in expansion states were significantly less likely to be diagnosed with stage IV disease, the most advanced form. In fact, the odds of an advanced diagnosis decreased by 7 percent each year following expansion, a pattern researchers attribute to increased access to mammogram screening among low-income women.

But the study revealed something else, something that troubled the researchers. Even as Medicaid expansion improved access to diagnosis, the proportion of patients actually receiving treatment declined across all states, regardless of expansion status. This was unexpected and concerning. Cancer diagnoses are rising nationally, yet fewer patients are being treated. The researchers could not explain why from their data alone, but the finding suggests that insurance coverage, while necessary, is not sufficient. Something else—infrastructure, specialist availability, patient preference, or other barriers—is preventing people from moving from diagnosis to care.

Dr. Amy Laughlin, the study's lead author and chief quality officer at the Orlando Health Cancer Institute, noted the paradox: "We know from other studies that cancer diagnoses are increasing. If we're then having less treatment received, are we not meeting that demand?" The finding raises questions about whether expansion states have the capacity to treat the patients they are now successfully identifying through screening.

The research also revealed an intriguing secondary finding: patients diagnosed in expansion states were 2.27 times more likely to receive treatment than those in non-expansion states, independent of whether they themselves had Medicaid. This suggests that expansion states possess some intrinsic advantage—better hospital infrastructure, more oncologists, stronger support systems—that benefits all patients, not just the newly insured. These factors were not detailed in the study but hint at deeper structural differences between regions.

Experts outside the study acknowledged both the significance and the limitations of the work. Dr. Katharine Yao, chair of the National Accreditation Program for Breast Centers, called the reduction in uninsured rates "striking" and described non-expansion as "a missed opportunity." But she also noted that the research raises as many questions as it answers: Is the decline in treatment due to stage migration, access issues, patient choice, or something else entirely? Future studies will need to track whether earlier detection actually translates into better survival rates, and whether rural and vulnerable populations specifically benefit from expansion.

The researchers' next steps are clear. They want to know if the earlier diagnoses in expansion states lead to longer lives. They want to understand whether rural patients and vulnerable populations see the same gains. And they want to measure the real-world impact of the novel therapies—immunotherapy, targeted drugs—that medicine has developed in recent years. The question, as one author framed it, is simple: how many patients actually benefit from these discoveries? If half the country's poor remain uninsured or underinsured, the answer may be: not enough.